Seeking Alpha

The EU grants orphan drug status to Endocyte's (ECYT +2.1%) folic acid solution for helping to...

The EU grants orphan drug status to Endocyte's (ECYT +2.1%) folic acid solution for helping to treat ovarian cancer. The solution is used as a pre-injection for the radiodiagnostic imaging agent, etarfolatide, to help select patients who can be treated with Endocyte's vintafolide drug, which it's developing with Merck and which is in Phase II and III cancer trials. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs